Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4

1(50.0%)

Phase 3

1(50.0%)

2Total

Phase 4(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05738460Unknown

Effects of IAP-EOGBSD on Offspring's Gut Microbiome and Immunity.

Role: collaborator

NCT05738473Unknown

Effects of IAP-EOGBSD on Maternal Vaginal Microbiome, Offspring's Gut Microbiome and Metabolites.

Role: collaborator

NCT05682131Phase 4Recruiting

South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol

Role: collaborator

NCT03492515Phase 3Unknown

Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia

Role: collaborator

NCT01784380Completed

The Potential Biochemical Diagnosis Criteria and Therapeutic Effect Indexes: Sex Hormone Binding Globulin Levels and Free Androgen Index in Blood of Patients With Polycystic Ovary Syndrome

Role: lead

All 5 trials loaded